Unlock the Editor’s Digest for free
Roula Khalaf, Editor of the FT, selects her favourite stories in this weekly newsletter.
UnitedHealth Group has announced that former chief executive Stephen Hemsley will be returning to his role as the current boss Andrew Witty steps down. This decision comes as the US healthcare giant’s shares have experienced a significant decline.
Witty’s departure from the top job is attributed to “personal reasons,” prompting the suspension of the group’s annual outlook. The news of Witty’s resignation caused UnitedHealth’s shares to plummet by almost 12% in early Wall Street trading, bringing the stock’s year-to-date loss to approximately 34%.
Having taken on the role of chief executive in 2021, Witty has guided the group through a challenging period. Just weeks ago, UnitedHealth revised its profit forecast downwards. Additionally, the company is still grappling with the aftermath of the tragic killing of Brian Thompson, the former CEO of its insurance division.
Hemsley, who served as CEO from 2006 to 2017, has been appointed as the executive chair and will continue to lead the board. In response to the recent setbacks, Hemsley expressed his disappointment and issued an apology during an investor call on Tuesday morning.
While no specific details were provided regarding Witty’s departure, Hemsley noted that Witty will remain as a senior adviser within the organization. UnitedHealthcare, known for its extensive insurance business and network of medical practices, recently revised its annual profit forecast due to unexpected spikes in demand for medical services, particularly from older patients.
In addition, the company is currently under investigation by US antitrust authorities due to its status as the largest health insurer in the country. The leadership changes at UnitedHealth coincide with efforts by the Trump administration to lower drug prices in the US. President Donald Trump recently mentioned plans to enable Americans to access medications directly from pharmaceutical companies, bypassing intermediaries like UnitedHealth, one of the leading pharmacy benefit managers in the nation.
The reshuffling at UnitedHealth reflects the challenges facing the healthcare industry, particularly in the wake of regulatory scrutiny and evolving market dynamics. As the company navigates these changes, stakeholders will be closely monitoring how Hemsley’s return and Witty’s departure will impact UnitedHealth’s future trajectory.
This article has been rewritten based on the original content provided above, incorporating HTML tags, key points, and relevant details to ensure a seamless integration into a WordPress platform.
